http://www.aldacorp.com/download/newsreleases/Swine_aph_flu_aph_27Apr09_aph_FINAL.pdf

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented
T36® technology. T36® has been proven to be effective against the H1N1 and H3N2 strains of swine flu and against SARS-like viruses.

The company trades on the TSX Venture Exchangeunder the symbol, “APH”, and is quoted on the OTCBB under the symbol, “APCSF”.

Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals